Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

Background Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden. A composite measure of total pain burden (TPB; frequency, severity, and duration) may provide a more comprehensive characterization of pai...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of headache and pain Ročník 21; číslo 1; s. 123 - 9
Hlavní autoři:	Ailani, Jessica, Andrews, J. Scott, Rettiganti, Mallikarjuna, Nicholson, Robert A.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Milan Springer Milan 17.10.2020 BMC
Témata:	Antibodies, Monoclonal, Humanized Burden of illness Chronic migraine Double-Blind Method Galcanezumab Headache Humans Internal Medicine Medicine Medicine & Public Health Migraine Migraine Disorders - drug therapy Neurology Pain Pain Medicine Quality of Life Research Article Treatment Outcome Chronic migraine Prevention Headache Burden of illness Pain Migraine Clinical trial Galcanezumab
ISSN:	1129-2369, 1129-2377, 1129-2377
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!